To assess the efficacy and safety of different doses of APD421 in the prevention of
post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV.
Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any
surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery
scheduled to last at least one hour from induction of anaesthesia), requiring at least one
overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past
history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use
for post-operative analgesia.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.